secwatch.observer — SEC 8-K summary
======================================

Issuer:     Century Therapeutics, Inc. (IPSC)
CIK:        0001850119
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-116808
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Century Therapeutics Q3 net loss $30.7M; cash $395.3M; CNTY-101 trial imminent
------------------------------------------------------------------------------

- Net loss $30.7M for Q3 2022 vs $26.0M in Q3 2021; R&D expenses rose to $25.9M.
- Cash, cash equivalents, and investments totaled $395.3M at Sep 30, 2022; runway into 2025.
- Full-year 2022 GAAP operating expense guidance lowered to $140M-$145M (incl. $10-$15M stock comp).
- Phase 1 ELiPSE-1 trial of CNTY-101 in B-cell malignancies to begin imminently after FDA clearance.
- Appointed Daphne Quimi and Timothy Walbert to Board; SITC data and R&D Day on Nov 11.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1850119/000110465922116808/0001104659-22-116808-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1850119/000110465922116808/tm2230058d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-116808

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer